Arizona's Off-Label Promotion Law May Hinge On Gottlieb

By Alexis Kellert, Weil Gotshal & Manges LLP (May 8, 2017, 3:54 PM EDT) -- In November, the U.S. Food and Drug Administration announced its decision to collect feedback regarding whether drug and device manufacturers should be allowed to promote their products for uses outside of their FDA-approved treatments (i.e., "off-label").[1] The mere fact that the FDA sought this type of public input on the issue marked a significant shift in the agency's enforcement regime, which has prohibited off-label advertising since the mid-1960s....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!